1. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). (2nd January 2018) Authors: Benyamine, Audrey; Loncle, Céline; Foucher, Etienne; Blazquez, Juan-Luis; Castanier, Céline; Chrétien, Anne-Sophie; Modesti, Mauro; Secq, Véronique; Chouaib, Salem; Gironella, Meritxell; Vila-Navarro, Elena; Montalto, Giuseppe; Dagorn, Jean-Charles; Dusetti, Nelson; Iovanna, Juan; Olive, Daniel Journal: Oncoimmunology Issue: Volume 7:Number 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗